Frequently Asked Questions
The market is segmented based on , By Product Type (Tear Stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Treatment (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Diagnosis (Comprehensive Eye Exam, Schirmer Test, Tear Osmolarity Test, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2029
.
The Global Dry Eye Syndrome Treatment Market size was valued at USD 5878.88 USD Billion in 2021.
The Global Dry Eye Syndrome Treatment Market is projected to grow at a CAGR of 9.22% during the forecast period of 2022 to 2029.
The major players operating in the market include , Eli Lilly and Company , AstraZeneca , Novartis AG , Johnson & Johnson Private Limited , Teva Pharmaceutical Industries , Merck & Co. , Allergan , Bausch Health Companies , Abbott , F. Hoffmann,La Roche , Pfizer , GlaxoSmithKline plc , Sanofi , Merck KGaA , Otsuka America Pharmaceutical , Akorn Operating Company LLC , Allostera Pharma , I,Med Pharma , Santen Pharmaceuticals Co. , AFT Pharmaceuticals , Novaliq GmbH ,.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
